Latest news with #CKD
Yahoo
a day ago
- Automotive
- Yahoo
Daimler Truck Signs Letter of Intent for Vehicle Assembly in Senegal
LEINFELDEN-ECHTERDINGEN, Germany & DAKAR, Senegal, July 03, 2025--(BUSINESS WIRE)--Daimler Truck has signed a Letter of Intent with the Government of Senegal and Global Truck Systems (GTS) to establish a local truck assembly plant. As part of the agreement, Daimler Truck will serve as the exclusive supplier of dismantled truck kits (CKD – Completely Knocked Down) and act as the project's technology partner. The Senegalese government and GTS have formed a joint venture to lead the assembly operations. Production is expected to begin as early as 2026, with vehicles reaching customers the following year. The plant will assemble various Mercedes-Benz truck model series, tailored for government use—such as the Ministry of Defense, fire brigades, and police—as well as private sector needs including waste collection, construction, logistics, and transportation. Franziska Cusumano, CEO of Mercedes-Benz Special Trucks, highlighted the strategic importance of the initiative: "The CKD delivery, transfer of know-how, and technical support reflect our partnership-based approach with the German Federal Government and the Republic of Senegal." Michael Dietz, CEO of Daimler Truck Middle East/Africa, added: "This project signals our long-term commitment to West Africa. Through local assembly, job creation, and technology transfer, we aim to contribute to regional economic development." Strong German-Senegalese Partnership Senegal has been a valued partner of German development cooperation for decades. Since 2019, both nations have worked under a bilateral reform partnership, which evolved into a climate and development partnership in 2023 through the Just Energy Transition Partnership. The CKD project is a direct outcome of this collaboration, promoting local industrial development and sustainability. Senegal's Commitment to Industrial Growth The Senegalese government is supporting the project by providing industrial land, offering customs and tax incentives, and facilitating local workforce training. This initiative aligns with Senegal's broader strategy to expand domestic production and meet growing mobility needs. GTS: Operational Lead GTS is responsible for setting up and operating the assembly plant. This includes recruiting and training personnel, planning production facilities, assembling vehicles from CKD kits, and equipping them with specialized bodies such as cranes or container frames. GTS will also oversee sales operations. Daimler Truck's Contribution Daimler Truck will ensure a reliable supply chain, enforce quality standards, and manage technology transfer. The company will also provide long-term service support, ensuring the high quality of locally assembled vehicles. This project is expected to create qualified local jobs and boost industrial capabilities in the region. Through this strategic partnership, Daimler Truck, GTS, and the Senegalese government are laying the groundwork for sustainable automotive manufacturing in West Africa, setting a benchmark for industrial cooperation, economic development, and technological advancement. Further information on Daimler Truck is available at: and Source: AETOSWire View source version on Contacts Lukas Hettmannsperger, +49 (0) 1703871112, Ulrike Burkhart, +49 (0) 1608613757, Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
a day ago
- Automotive
- Business Wire
Daimler Truck Signs Letter of Intent for Vehicle Assembly in Senegal
LEINFELDEN-ECHTERDINGEN, Germany & DAKAR, Senegal--(BUSINESS WIRE)--Daimler Truck has signed a Letter of Intent with the Government of Senegal and Global Truck Systems (GTS) to establish a local truck assembly plant. As part of the agreement, Daimler Truck will serve as the exclusive supplier of dismantled truck kits (CKD – Completely Knocked Down) and act as the project's technology partner. The Senegalese government and GTS have formed a joint venture to lead the assembly operations. Production is expected to begin as early as 2026, with vehicles reaching customers the following year. The plant will assemble various Mercedes-Benz truck model series, tailored for government use—such as the Ministry of Defense, fire brigades, and police—as well as private sector needs including waste collection, construction, logistics, and transportation. Franziska Cusumano, CEO of Mercedes-Benz Special Trucks, highlighted the strategic importance of the initiative: 'The CKD delivery, transfer of know-how, and technical support reflect our partnership-based approach with the German Federal Government and the Republic of Senegal.' Michael Dietz, CEO of Daimler Truck Middle East/Africa, added: 'This project signals our long-term commitment to West Africa. Through local assembly, job creation, and technology transfer, we aim to contribute to regional economic development.' Strong German-Senegalese Partnership Senegal has been a valued partner of German development cooperation for decades. Since 2019, both nations have worked under a bilateral reform partnership, which evolved into a climate and development partnership in 2023 through the Just Energy Transition Partnership. The CKD project is a direct outcome of this collaboration, promoting local industrial development and sustainability. Senegal's Commitment to Industrial Growth The Senegalese government is supporting the project by providing industrial land, offering customs and tax incentives, and facilitating local workforce training. This initiative aligns with Senegal's broader strategy to expand domestic production and meet growing mobility needs. GTS: Operational Lead GTS is responsible for setting up and operating the assembly plant. This includes recruiting and training personnel, planning production facilities, assembling vehicles from CKD kits, and equipping them with specialized bodies such as cranes or container frames. GTS will also oversee sales operations. Daimler Truck's Contribution Daimler Truck will ensure a reliable supply chain, enforce quality standards, and manage technology transfer. The company will also provide long-term service support, ensuring the high quality of locally assembled vehicles. This project is expected to create qualified local jobs and boost industrial capabilities in the region. Through this strategic partnership, Daimler Truck, GTS, and the Senegalese government are laying the groundwork for sustainable automotive manufacturing in West Africa, setting a benchmark for industrial cooperation, economic development, and technological advancement.
Yahoo
4 days ago
- Business
- Yahoo
Mineralys Therapeutics Reports Positive Topline Data from Phase 2 Explore-CKD Trial of Lorundrostat
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) is one of the 12 Small Cap Stocks with High Upside Potential. On June 17, Mineralys Therapeutics, Inc. (NASDAQ:MLYS) reported positive topline data from its Phase 2 Explore-CKD trial of lorundrostat. The company achieved positive topline data for the ongoing trials of lorundrostat for the treatment of subjects with hypertension and comorbid CKD. The crossover trial met the primary endpoint and showed clinically meaningful reductions in both systolic automated office blood pressure (AOBP) and urine albumin-to-creatinine ratio (UACR). The 25 mg dosage of lorundrostat achieved a 9.3 mmHg reduction in AOBP and a 7.5 mmHg placebo-adjusted reduction at four weeks. Whereas, lorundrostat showed a reduction in pre-defined endpoint spot urine UACR of 31%. A medical researcher carefully inspecting a Petri dish containing biopharmaceutical cultures. 'Explore-CKD established that lorundrostat 25 mg once daily has a favorable clinical profile for this patient population. Along with the successful pivotal trials, Launch-HTN and Advance-HTN, and the ongoing open-label extension trial, these results comprise the core package for our planned NDA submission,' stated Jon Congleton, Chief Executive Officer of Mineralys. The company continues to enroll subjects with OSA and uncontrolled hypertension for its ongoing Explore-OSA trials. Mineralys Therapeutics, Inc. (NASDAQ:MLYS) is a clinical-stage biopharmaceutical company that develops medicines to target diseases driven by dysregulated aldosterone in the U.S. While we acknowledge the potential of MLYS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Sign in to access your portfolio
Associated Press
4 days ago
- Business
- Associated Press
Kaplan Fox & Kilsheimer LLP is Investigating Unicycive Therapeutics, Inc. (UNCY) for Potential Securities Law Violations
NEW YORK, NY - June 30, 2025 ( NEWMEDIAWIRE ) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Unicycive Therapeutics, Inc. ('Unicycive' or the 'Company') (NASDAQ: UNCY). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are an Unicycive investor and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing [email protected] or by calling (212) 329-8571. On June 10, 2025, before the market opened, Unicycive issued a press release announcing an 'update on its New Drug Application (NDA) for oxlanthanum carbonate (OLC) to treat hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis.' Hyperphosphatemia is a medical condition that effects over 450,000 individuals annually and 'occurs in nearly all patients with End Stage Renal Disease', 'requir[ing] medication to control their phosphate levels.' The Company revealed that the Federal Drug Administration ('FDA') 'identified deficiencies in cGMP compliance at a third-party manufacturing vendor following an FDA inspection.' Following this news, the price of Unicycive stock fell $3.68 per share, over 40%, to close at $5.32 per share on June 10, 2024 on heavy trading volume. Then, on June 30, 2025, Unicycive announced receipt of a Complete Response Letter for OLC for the treatment of hyperphosphatemia in patients with CKD on dialysis (the 'CRL'), thereby indicating that the agency denied approval of the Company's NDA in its current form. The Company stated that the CRL 'cited deficiencies previously identified at a third-party manufacturing vendor. . . ' and that it has requested a meeting with the FDA. Following this news, the price of Unicycive stock fell over 25% during intraday trading on June 30, 2025 on heavy trading volume. WHY CONTACT KAPLAN FOX - Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey. With over 50 years of experience in securities litigation, Kaplan Fox offers the professional experience and track record that clients demand. Through prosecuting cases on the federal and state levels, Kaplan Fox has successfully shaped the law through winning many important decisions on behalf of our clients. For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. If you have any questions about this investigation, please contact: CONTACT: Jeffrey P. Campisi KAPLAN FOX & KILSHEIMER LLP 800 Third Avenue, 38th Floor New York, New York 10022 (212) 329-8571 [email protected] Laurence D. King KAPLAN FOX & KILSHEIMER LLP 1999 Harrison Street, Suite 1501 Oakland, California 94612 (415) 772-4704 [email protected] Contacting or submitting information to Kaplan Fox & Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.
Hindustan Times
25-06-2025
- Politics
- Hindustan Times
Akal Takht summons CKD panel over ‘non-compliance' of Sikh ‘maryada'
Jun 25, 2025 06:14 AM IST Akal Takht acting jathedar Giani Kuldeep Singh Gargaj has summoned the executive committee of the Chief Khalsa Diwan (CKD) over various issues, including non-compliance of Sikh 'maryada' by its majority members, said spokesperson on Tuesday. Akal Takht acting jathedar Giani Kuldeep Singh Gargaj has summoned the executive committee of the Chief Khalsa Diwan (CKD) over various issues, including non-compliance of Sikh 'maryada' by its majority members, said spokesperson on Tuesday. (HT File) Bagicha Singh, in-charge of Akal Takht secretariat, said the CKD executive committee has been asked to appear before the highest Sikh temporal seat in person in 15 days following a number of complaints received by the Akal Takht secretariat. The summon was issued to the CKD president Dr Inderbir Singh Nijjar, who is also AAP MLA from Amritsar south. As per sources, the complaints claim that majority of the members are not 'amritdhari'. The CKD is a historic Sikh organisation which is nearly 12 years old and runs more than 50 educational institutes in Punjab. Dr Nijjar said, 'Akal Takht is supreme for Sikhs. We are answerable to it.'
